These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28478613)

  • 1. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
    Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.
    Dedić Plavetić N; Jakić-Razumović J; Kulić A; Sirotković-Skerlev M; Barić M; Vrbanec D
    Pathol Oncol Res; 2015 Apr; 21(2):315-24. PubMed ID: 25096394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
    Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
    PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
    Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
    Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity.
    Böger C; Behrens HM; Röcken C
    J Surg Oncol; 2016 Jan; 113(1):46-54. PubMed ID: 26709194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
    Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
    Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
    Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
    Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
    Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
    Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of Ki67 visual scoring app compared to eyeball estimate and digital image analysis and its prognostic significance in hormone receptor-positive breast cancer.
    Arun I; Venkatesh S; Ahmed R; Agrawal SK; Leung SCY
    APMIS; 2021 Aug; 129(8):489-502. PubMed ID: 34053140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
    Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
    Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.
    Liu JJ; Shen R; Chen L; Ye Y; He G; Hua K; Jarjoura D; Nakano T; Ramesh GK; Shapiro CL; Barsky SH; Gao JX
    Int J Clin Exp Pathol; 2010 Mar; 3(4):328-37. PubMed ID: 20490325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.
    Khoury T; Zirpoli G; Cohen SM; Geradts J; Omilian A; Davis W; Bshara W; Miller R; Mathews MM; Troester M; Palmer JR; Ambrosone CB
    Am J Clin Pathol; 2017 Aug; 148(2):108-118. PubMed ID: 28898983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
    Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
    Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations.
    Erices-Leclercq M; Lubig S; Förster F; Förster R; Baldus S; Rudlowski C; Schröder L
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):441-447. PubMed ID: 33991247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.
    Aleskandarany MA; Green AR; Ashankyty I; Elmouna A; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Jul; 158(2):287-95. PubMed ID: 27380874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.
    Bankhead P; Fernández JA; McArt DG; Boyle DP; Li G; Loughrey MB; Irwin GW; Harkin DP; James JA; McQuaid S; Salto-Tellez M; Hamilton PW
    Lab Invest; 2018 Jan; 98(1):15-26. PubMed ID: 29251737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
    Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
    Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.